EIKNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Eikon Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.70+0.28 (+3.77%)
Close on Oct 19, 2026
- Market cap
- $416.90M
- P/E (TTM)
- –
- Dividend yield
- –
Eikon Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Eikon Therapeutics | Industry median |
|---|---|---|
| Market Cap | $417.07M | $166.30M |
| Enterprise Value | -$114.11M | $88.19M |
| PB Ratio | 0.89 | 2.03 |
| P/TBV Ratio | 0.89 | 2.29 |
Balance sheet
| Measure | Eikon Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $531.18M | $61.43M |
| Net Cash (Debt) | $531.18M | $15.35M |
| Net Cash Per Share | $9.81 | $0.66 |
| Equity (Book Value) | $466.50M | $49.09M |
| Book Value Per Share | $8.61 | $1.37 |
| Tangible Book Value | $466.50M | $23.52M |
| Working Capital | $491.68M | $76.81M |
Financial position
| Measure | Eikon Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 9.89 | 3.34 |
| Quick Ratio | 9.61 | 2.44 |
Efficiency
| Measure | Eikon Therapeutics | Industry median |
|---|---|---|
| Employee Count | 384 | 74 |
Shares
| Measure | Eikon Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 54,165,000 | 58,127,000 |
| Shares Change (QoQ) | 0.02% | 0.54% |
| Float | 38,219,200 | 49,136,700 |
| Shares Held by Insiders | 29.4% | 11.6% |
| Shares Held by Institutions | 48.9% | 59.4% |
Scores
| Measure | Eikon Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -0.40 | -0.22 |
Calculated by StockData from Eikon Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.